- Home
- ACAD vs TWST Comparison
ACAD vs TWST Comparison
Compare ACAD & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- TWST
- Stock Information
- Founded
- ACAD 1993
- TWST 2013
- Country
- ACAD United States
- TWST United States
- Employees
- ACAD N/A
- TWST N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- TWST Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACAD Health Care
- TWST Health Care
- Exchange
- ACAD Nasdaq
- TWST Nasdaq
- Market Cap
- ACAD 2.8B
- TWST 2.6B
- IPO Year
- ACAD 2004
- TWST 2018
- Fundamental
- Price
- ACAD $16.61
- TWST $39.26
- Analyst Decision
- ACAD Buy
- TWST Buy
- Analyst Count
- ACAD 17
- TWST 10
- Target Price
- ACAD $24.00
- TWST $52.50
- AVG Volume (30 Days)
- ACAD 1.5M
- TWST 1.1M
- Earning Date
- ACAD 05-07-2025
- TWST 05-01-2025
- Dividend Yield
- ACAD N/A
- TWST N/A
- EPS Growth
- ACAD N/A
- TWST N/A
- EPS
- ACAD 1.36
- TWST N/A
- Revenue
- ACAD $957,797,000.00
- TWST $330,189,000.00
- Revenue This Year
- ACAD $13.07
- TWST $22.62
- Revenue Next Year
- ACAD $9.97
- TWST $17.76
- P/E Ratio
- ACAD $12.28
- TWST N/A
- Revenue Growth
- ACAD 31.85
- TWST 25.85
- 52 Week Low
- ACAD $14.15
- TWST $27.41
- 52 Week High
- ACAD $20.68
- TWST $60.90
- Technical
- Relative Strength Index (RSI)
- ACAD 36.91
- TWST 41.99
- Support Level
- ACAD $16.86
- TWST $40.50
- Resistance Level
- ACAD $17.31
- TWST $44.94
- Average True Range (ATR)
- ACAD 0.51
- TWST 2.38
- MACD
- ACAD -0.00
- TWST 0.17
- Stochastic Oscillator
- ACAD 23.24
- TWST 26.32
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About TWST Twist Bioscience Corporation
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.